ACTINIUM PHARMACEUTICALS 1 RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHMon, 01 Jun 2026 07:38:46 +0200https://images.finanzen.net/images/finanzen_net_neu.gifACTINIUM PHARMACEUTICALS 1 RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netActinium Pharmaceuticals gab Ergebnis zum abgelaufenen Quartal bekanntSun, 10 May 2026 06:35:06 +0200https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-gab-ergebnis-zum-abgelaufenen-quartal-bekannt-15673894Actinium Pharmaceuticals stellte am 08.05.2026 die jüngste Quartalsbilanz zum am 31.03.2026 abgelaufenen Quartal vor.Für das jüngste Jahresviertel wies das Unternehmen ein EPS von -0,18 USD je Aktie ...

]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-gab-ergebnis-zum-abgelaufenen-quartal-bekannt-15673894Actinium Pharmaceuticals gewährte Anlegern Blick in die Bücher Wed, 01 Apr 2026 06:35:06 +0200https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-gewaehrte-anlegern-blick-in-die-buecher-15588214Actinium Pharmaceuticals hat am 30.03.2026 das Zahlenwerk zum am 31.12.2025 ausgelaufenen Quartal vorgelegt.Actinium Pharmaceuticals hat im jüngsten Jahresviertel einen Verlust von 0,19 USD je Aktie ...

]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-gewaehrte-anlegern-blick-in-die-buecher-15588214Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negat...Fri, 12 Dec 2025 14:45:00 +0100https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-presents-new-preclinical-data-demonstrating-potent-anti-tumor-activity-of-atnm-400-across-multiple-breast-cancer-subtypes-including-hormone-receptor-positive-triple-negat-15355319

-       ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the ...

]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-presents-new-preclinical-data-demonstrating-potent-anti-tumor-activity-of-atnm-400-across-multiple-breast-cancer-subtypes-including-hormone-receptor-positive-triple-negat-15355319Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Present...Mon, 01 Dec 2025 14:45:00 +0100https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-announces-atnm-400-data-demonstrating-potent-efficacy-in-triple-negative-breast-cancer-and-ability-to-overcome-endocrine-and-her2-targeted-therapy-resistance-being-present-15324946
  •  Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment options

  • ATNM-400 overcomes HER2 therapy resistance ...

    ]]>https://www.finanzen.net/nachricht/aktien/actinium-pharmaceuticals-announces-atnm-400-data-demonstrating-potent-efficacy-in-triple-negative-breast-cancer-and-ability-to-overcome-endocrine-and-her2-targeted-therapy-resistance-being-present-15324946